Results 31 to 40 of about 1,148,410 (327)
McGill Journal of Medicine, 2020 In response to "TRIPS agreement and public health" by Junaid Subhan.
Bishnu Rath Giri, P. Ravi Shankar
doaj +1 more source
Can’t Buy Me Rights! The Contractual Structure of Asymmetrical Inter-firm Collaborations [PDF]
, 2006 The efficient allocation of control rights in inter-firm collaborations is a widely emphasized issue. In this paper, I empirically identify control rights and the allocation of these rights using a unique survey data set on collaborations between ...
Häussler, Carolin
core +2 more sources
Strange Bedfellows: Native American Tribes, Big Pharma, and the Legitimacy of Their Alliance [PDF]
, 2006 Lost in the cacophony surrounding the debate about high drug prices is the fundamental principle that pharmaceutical innovation will not occur without the prospect of outsized returns enabled through market exclusivity.
Chenine, Moustafa +2 more
core +2 more sources
A Review about Regulatory Status and Recent Patents of Pharmaceutical Co-Crystals
Advanced Pharmaceutical Bulletin, 2018 Pharmaceutical Co-crystals are not new, they have gained much attention since the last decade among scientists and pharmaceutical industry. Pharmaceutical co-crystals are multicomponent systems composed of two or more molecules and held together by non ...
Arun Kumar, Sandeep Kumar, A. Nanda
semanticscholar +1 more source
The African Journal of Information and Communication, 2015 Pharmaceutical firms’ use of strategic patenting to influence the markets within which their patented inventions sit is legally questionable. Such patenting entails filing patents with the intention of blocking potential competitors from innovating ...
Vuyisile Hobololo
doaj +3 more sources
Pharmaceutical patents: General characteristics and current issues in the international context [PDF]
Pravni Zapisi, 2014 A patent can be defined as an exclusive right that is granted to the patent owner, which allows him to prevent others from making, selling, importing or using the invention, without license or authorization for a period of 20 years.
Lasić Ines
doaj
Development of Biosimilars in Brazil
Fronteiras: Journal of Social, Technological and Environmental Science, 2016 This article presents a brief overview of the biosimilar industry in Brazil and in the world. Biosimilars are drugs originating from therapeutic or biological proteins, whose patents are expired or are going to expire.
Eduardo Braz Pereira Gomes +4 more
doaj +1 more source
Awaking the Sleeping Dragon: The Evolving Chinese Patent Laws and its Implications for Pharmeceutical Patents [PDF]
, 2011 Part I of this Comment will discuss the development of the Chinese IP system and discuss why it has been ineffective in protecting pharmaceutical patents by comparing it to the US patent system.
Wu, Rachel T.
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender +17 more
wiley +1 more source
SAGE Open, 2021 Do different pharmaceutical product liability regimes in different countries induce propensity to patent? We exploit the variation in pharmaceutical liability and litigation rules across firms in the pharmaceutical industry and countries to explain the ...
Mitja Kovac, Salvini Datta, Rok Spruk
doaj +1 more source